JMDC stock came into this earnings print on a solid run, with the share price up about 11% over the past week and month, and trading on a rich 33.5x trailing P/E. That set the bar high for Q1 2027. The headline this quarter is pressure on profitability rather than revenue scale. Basic earnings per share for Q1 landed at ¥17.28 on revenue of ¥12,605m, leaving investors to question whether the premium valuation and double digit growth forecasts still feel comfortable on a multi year view.
Is JMDC's 33.5x P/E simply pricing in strong growth, or is the market stretching too far on margins and forecasts? Compare the current share price with fair value in the valuation analysis for JMDC
Q1 2027 Earnings Summary
- Revenue (Q1 2027 vs Q1 2026): ¥12,605m vs. ¥10,725m (up about 17.5%)
- Net Income (Excl. Extra Items, Q1 2027 vs Q1 2026): ¥1,131m vs. ¥966m (up about 17.1%)
- Basic EPS (Q1 2027 vs Q1 2026): ¥17.28 vs. ¥14.78 (up about 17.0%)
- Trailing 12 Month Basic EPS (Q1 2027 vs Q1 2026): ¥105.93 vs. ¥93.24 (up about 13.7%)
Tired of scrolling through dense earnings reports and rows of figures to make sense of JMDC? Get the full visual picture of JMDC's valuation and recent earnings trends in an easy-to-scan format with the company report for JMDC.
JMDC earnings support resilient growth story
For investors leaning bullish on JMDC, the latest quarter broadly supports a steady growth narrative. Revenue for Q1 2027 reached ¥12,605m compared with ¥10,725m in Q1 2026. Basic EPS moved to ¥17.28 from ¥14.78. Trailing 12 month EPS also rose to ¥105.93 from ¥93.24. That combination suggests the core healthcare data and telemedicine model is still scaling without an obvious hit to earnings power. This aligns with views that JMDC can build a recurring, data driven franchise with reasonably consistent financial momentum.
Profit pressure keeps JMDC risk debate alive
Bears worried about profitability and execution still have material questions to ask after this print. Net income excluding extra items increased to ¥1,131m from ¥966m, yet management commentary highlights pressure on margins rather than pure top line scale. That tension between revenue growth and profitability keeps the regulatory, cost and contract risk discussion relevant for JMDC. The new stock option grants also introduce potential dilution if earnings growth does not keep pace, which matters for anyone concerned about balancing long term incentives with per share outcomes.
After JMDC flagging margin strain and fresh stock option dilution, are these issues isolated or early stress signals? Review the risk analysis for JMDC which shows 1 important warning sign.Stay Ahead With JMDC Insights
If JMDC's premium 33.5x P/E, recent earnings momentum and questions around margins have your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch how the story develops. Once you have a position, use the Portfolio Command Center to cut through noise and focus on the key updates that matter to your holdings. For a broader view on how other investors are thinking about JMDC and similar stocks, tap into the Community to see different perspectives and debate the latest news. By surfacing potential catalysts and risks early, Simply Wall St helps you stay one step ahead of the market and make decisions with more confidence.
Seeking Fresh Alternatives Beyond JMDC
Markets move fast and fresh opportunities do not wait. Scan curated stock ideas with real momentum while they are still under the radar for now. Get in early.
- Fast track your hunt for resilient compounders by reviewing a curated 56 resilient stocks with low risk scores that aims to keep portfolio swings in check while momentum is still building.
- Spot cash generative winners before they are widely followed by assessing the hand picked 17 high quality undervalued stocks while the gap between fundamentals and price still matters.
- Ride structural trends in automation by scanning the focused 36 robotics and automation stocks before capital floods in and the most compelling entry points start dropping.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com